RHYTHM PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share data)


· · December 31, · · December 31,
	2024		2023

Assets
Current assets: · ·
Cash and cash equivalents		$89,137		$60,081
Short-term investments		231,428		215,765
Accounts receivable, net		18,512		14,867
Inventory		18,741		8,624
Prepaid expenses and other current assets		16,382		8,931
Total current assets		374,200		308,268
Property and equipment, net		632		1,341
Right-of-use asset		3,477		781
Intangible assets, net		6,174		7,028
Restricted cash		464		328
Other long-term assets		7,326		14,999
Total assets		$392,273		$332,745
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable		$12,328		$4,885
Accrued expenses and other current liabilities		62,658		48,262
Other current liability - LG Chem		37,704		—
Deferred revenue		1,286		1,286
Deferred royalty obligation, current		1,541		—
Lease liability		—		770
Total current liabilities		115,517		55,203
Long-term liabilities:
Deferred royalty obligation		108,269		106,143
Lease liability, non-current		3,938		490
Derivative liability		—		1,150
Total liabilities		227,724		162,986
Commitments and contingencies (Note 12)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively. Liquidation preference of $150,000 as of December 31, 2024.		142,820		—
Stockholders’ equity:
Common stock, $0.001 par value: 120,000,000 shares authorized; 62,390,654 and 59,426,559 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively		61		59
Additional paid-in capital		1,177,045		1,064,302
Accumulated other comprehensive (loss) income		(39)		134
Accumulated deficit		(1,155,338)		(894,736)
Total stockholders’ equity		21,729		169,759
Total liabilities, convertible preferred stock and stockholders’ equity		$392,273		$332,745

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.